Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

528 TERBINAFINE
(1998): Litt JZ, Beachwood, OH (personal case) (observation)
(1997): Hall M+, Arch Dermatol 133, 1213 (0.3%)
(1995): Wachs F+, Arch Dermatol 131, 960 (passim)
(1990): Villars V+, JDermatolTreat1, 33
Psoriasis
(2007): Kim BS+, J Korean Med Sci 22(1), 167
(2003): Szepietowski JC, Acta Dermatovenerol Croat 11(1), 17
(2000): Le Guyadec T+, Ann Dermatol Venereol (French)
127, 279
(1999): Pauluzzi P+, Acta Derm Venereol 79(5), 389
(1998): Gupta AK+, Br J Dermatol 138, 529 (2 patients)
(1998): Papa CA+, JAmAcadDermatol39, 115
(1998): Wilson NJ+, Br J Dermatol 139, 168
(1997): Gupta AK+, JAmAcadDermatol36, 858
(1995): Gupta AK+, unpublished findings
(1995): Wachs F+, Arch Dermatol 131, 960 (erythema annulare
centrifugum-like [sic])
Pustules
(1999): Bennett ML+, Int J Dermatol 38, 596
Rash (sic) (5.6%)
(2006): Danielsen AG+, Ugeskr Laeger 168(44), 3825
(2005): Gupta AK+, J Drugs Dermatol 4(3), 302
(1995): Haroon TS+, Br J Dermatol 135, 86
Side effects (sic) (2.7%)
(1990): Villars V+, JDermatolTreat1, 33
Stevens–Johnson syndrome
(2006): Terrab Z+, Ann Dermatol Venereol 133(5 Pt 1), 463
(1999): Rosen R (from Internet) (observation)
(1994): Rzany B+, JAmAcadDermatol30, 509
Toxic epidermal necrolysis
(1996): White SI+, Br J Dermatol 134, 188
(1994): Carstens J+, Acta Derm Venereol (Stockh) 74, 391
(1993): Beutler M+, BMJ 307, 26
Toxicoderma
(1997): Hall M+, Arch Dermatol 133, 1213
Urticaria (